ray__
Tally.bio: a free terminal for the biotech and pharma market
It's true that clinical trials are a big cost center for drug development, but there is an argument for mitigating failure here earlier in the process through better technology development. Some of this will come from AI and some of it from better experimental methods for probing biology. One of my favorite efforts in this area is OpenADMET, which combines ML and experimental methods for addressing tox-related issues in drug discovery, which are common causes for failure in the later (more expensive) clinical trial stages:
https://www.nature.com/articles/s41467-026-73410-8 https://openadmet.org
How to avoid AI brainrot – Miles Cranmer
AI-ready biological data: $1.8B global commitment
Television
CS 312: Deep Learning Alchemy
Stripe acquires Clerky
Bonsai, a new distortion-free method for high-dimensional data visualization
Ask HN: What Happened to dLLMs?
Diffusion LLMs (dLLMs) seemed so promising a year ago, but I don't see much about them now. What happened?
Gamgee
A Workaphile's Apology
The Pedagogy Behind the Studio
Macos27.kimi.page
Decoy Font
Learning from experience instead of curated datasets
Capable
Baby Pictures
The Unreasonable Redundancy of Nature's Protein Folds
UMA Playground
Presumably the underlying model here is also an LLM? To what degree is it "fine-tuned", or is it just given a set of tools to build a good picture of cluster usage?
To be clear I don't think that LLMs are sentient, but the appeal in studying them is similar to biology in that you get to dissect a highly complex system with comparatively crude tools.